Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site

血

• 批准号: 10430215
• 负责人: FREDERICK APPELBAUM
• 金额: $ 5.94万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10430215
• 关键词: Blood; Marrow; Clinical; Trials; Network

Project Summary/Abstract Over the last 15 years, the BMT CTN has effectively addressed key issues in HCT, including donor selection, choice of preparative regimens, prevention of post-transplant infection, prevention and treatment of graft- versus-host disease and the indications for HCT in the treatment of specific diseases, through the conduct of 37 clinical trials. The Fred Hutch Transplant Program has played an important role in the success of the BMT CTN since its inception, serving as one of its Core Clinical Centers. There are a number of features of the Fred Hutch Transplant Program that enhances its value as a Core Clinical Center. (1) The volume of clinical activity at the Hutch allows us to successfully recruit and enroll patients on BMT CTN clinical trials, including patients with rare diseases. The Hutch’s performance in reaching its BMT CTN accrual targets over the last four year has been rated by the BMT CTN as “outstanding.” (2) Our long and deep experience with HCT provides outstanding clinical outcomes. For the past 3 years running, we have exceeded the 95% confidence limits for survival as calculated by the center-specific outcomes measures of the Center for International Blood and Marrow Transplant Research (CIBMTR). (3) The faculty of the Fred Hutch Transplant Program includes a large number of investigators, all focused on various aspects of HCT. The breadth and depth of this group whose NIH funding includes 6 Program Projects, 26 RO1s, and numerous other awards, helps insure that we will continue to provide important scientific contributions to the network. Each year for the last 4 years, our group has been rated as “outstanding” by the BMT CTN for our scientific and administrative efforts. (4) The Fred Hutch has extensive experience with novel cell therapies including stem cell expansion, genetic engineering of T cells, and correction of inborn errors, which are areas of specific interest noted by the NHLBI and the NCI. (5) The faculty of the Fred Hutch have enthusiastically collaborated with other members of the BMT CTN to help achieve the networks research goals over the past funding periods and is committed to continuing to do so.

项目摘要/摘要 在过去的15年里，BMT CTN有效地解决了HCT中的关键问题，包括捐赠者的选择， 选择准备方案，预防移植后感染，预防和治疗移植物。 抗宿主疾病和HCT在治疗特定疾病中的适应症，通过开展 37项临床试验。弗雷德·哈奇移植计划在骨髓移植的成功中发挥了重要作用 CTN自成立以来，一直是其核心临床中心之一。FRED有很多特点 Hutch移植计划，增强其作为核心临床中心的价值。(1)临床活动量 At The Hutch允许我们成功招募和招募患者参加BMT CTN临床试验，包括患者 患有罕见的疾病。和记黄埔过去四年在实现BMT CTN应计目标方面的表现 已被BMT CTN评为“杰出”。(2)我们在HCT方面的长期而深入的经验提供了 出色的临床效果。在过去的三年里，我们已经超过了95%的置信度 根据国际血液和营养中心的中心特定结果指标计算的存活率 骨髓移植研究(CIBMTR)(3)弗雷德·哈奇移植计划的教职员工包括一名 许多调查人员，都专注于HCT的各个方面。这个群体的广度和深度 NIH的资金包括6个计划项目，26个RO1和许多其他奖项，帮助确保我们将 继续为该网络提供重要的科学贡献。在过去的四年里，我们组每年都 由于我们的科学和管理努力，已被BMT CTN评为“杰出”。(4)《弗雷德》 Hutch在新的细胞疗法方面拥有丰富的经验，包括干细胞扩增、基因工程和 T细胞和先天错误的纠正，这是NHLBI和NCI特别感兴趣的领域。 (5)弗雷德·哈奇的教职员工与BMT CTN的其他成员热情合作，以 在过去的资助期间帮助实现网络研究目标，并致力于继续 所以。